



European Monitoring Centre
for Drugs and Drug Addiction

Final Agenda
**EU expert meeting on the EMCDDA key epidemiological indicator Drug
Related Infectious Diseases (DRID), EMCDDA, 10-11 October 2012**

Venue: EMCDDA, Cais do Sodré, Lisbon

Objectives:

Day 1

- To review progress in the ongoing DRID implementation
- To discuss a future strategy for DRID

Day 2

- Update on recent studies on DRID epidemiology and interventions

Wednesday 10 October

Chair: Lucas Wiessing

9.00 - 10.30 Review progress in ongoing DRID implementation

- Lucas Wiessing – Introduction
- Alan Lodwick – Evaluation of EMCDDA key indicator expert meetings
- Andre Noor – Progress on Fonte and Standard Table 9 implementation
- Sandrine Sleiman – Update on the DRID implementation assessment
- Linda Montanari – Update on TDI revision and inclusion of DRID variables
- Sandrine Sleiman – EMCDDA DRID support in neighbouring countries
- Discussion

10.30 - 11.00 Coffee-break

11.00 - 13.00 Toolkit progress and future strategies for DRID

- Introduction
- Magdalena Rosinska – Update on module “Serobehavioural studies”
- Views on DRID and future strategy (short presentations by: Hans Blystad, Maria Jose Bravo, Anastasios Fotiou, Vivian Hope, Tomas Zabransky)
- Discussion

13.00 - 14.30 Lunch

14.30 - 16.00 Parallel workshops on future DRID strategy and toolkit

16.00 - 16.30 Coffee-break

16.30 - 18.00 Plenary reporting and discussion

18.00 - 19.00 Reception at EMCDDA premises

Thursday 11 October

Studies on DRID epidemiology and interventions

Chair: Lucas Wiessing

9.00 - 10.30

- Marica Ferri – EMCDDA systematic review of HCV among people who inject drugs in Europe: one method for multiple purposes
- Vivian Hope – The introduction of hepatitis C avidity and HBsAg testing into the Unlinked Anonymous Monitoring Survey of PWID in the UK
- Vivian Hope – A sero-behavioural survey of blood borne viruses among injectors of Image and Performance Enhancing Drugs
- Kaat Bollaerts – Drug related infectious diseases and psychiatric comorbidity among IDUs in Belgium, preliminary results of a serobehavioral prevalence study

10.30 - 11.00 Coffee-break

11.00 - 12.45

- Anna Tarjan – Changes and risks due to new injecting patterns in Hungary
- Anda Karnite – The association between injecting drug use and HIV outcome measures in Latvia
- Martin Busch – comparing the HIV cohort study and DRID monitoring in Austria
- Laura Fernández – Core Indicators to Monitor Community Based Voluntary Counselling and Testing (HIV-COBATEST Project) and Pilot study for the implementation of rapid HIV and HCV test in Harm Reduction Programs for intravenous drug users
- Ruth Zimmerman – Serobehavioural pilot study in Berlin and Essen

12.45 - 14.15 Lunch

Chair: Dagmar Hedrich

14.15 - 15.30

- Teodora Groshkova – HCV treatment uptake among people who inject drugs: results from an EMCDDA expert meeting
- Geert Robaey, International network on Hepatitis in Substance Users (INHSU) – HCV guidelines
- Jenneke van Ditzhuijzen – Improving Access to HIV/TB testing for marginalized groups (Impact Health programme project)

15.30 - 16.00 Coffee-break

16.00 - 16.45

- Henrique Barros – TB diagnosis and treatment among PWID: a Portuguese experience
- Vana Sypsa and Angelos Hatzakis – An integrated prevention initiative to stop HIV-1 outbreak among IDUs in Athens Metropolitan Area: preliminary data of the RDS study

16.45 End of DRID meeting